AMT-101-202 A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

NCT04583358

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Applied Molecular Transport Inc

AMT-101 is being developed for use in patients with ulcerative colitis. We hope to learn how safe and beneficial this investigational drug is in research participants with ulcerative colitis. “Investigational” means that the drug being tested has not been approved for routine clinical use. You were selected as a possible participant in this study because you have been diagnosed with ulcerative colitis.

This study is currently enrolling.